WHO/HIV/2014.1
© World Health Organization 2014
Title: Monitoring for renal toxicity in people receiving tenofovir and on tenofovir toxicity and how it affects disability-adjusted life-years and quality-adjusted life-years Contents 1. 2. 3. 4. 5. 5.1. 5.2. 5.3. 5.4. PICO question ....................................................................................................................................... 1 Search strategy ...................................................................................................................................... 2 Flow diagram of screening process ....................................................................................................... 6 Evidence summaries ............................................................................................................................. 7 Bibliography of included studies .......................................................................................................... 8 Systematic review on monitoring and diagnostic tests ..................................................................... 8 Systematic review on toxicity in adults ............................................................................................ 9 Systematic review on toxicity in children and adolescents ............................................................. 16 Systematic review on toxicity during pregnancy ............................................................................ 16
5.5. Systematic review on how tenofovir toxicity affects disability-adjusted life-years and qualityadjusted life-years ....................................................................................................................................... 17 5.6. Evidence from non-randomized (observational) studies with high risk of bias .............................. 18
1. PICO question a P I C O b P I C O Renal toxicity monitoring with ARV regimen containing tenofovir (TDF) Adults (including pregnant or breastfeeding women), adolescents and children living with HIV using TDF-containing regimens Baseline + regular urinalysis and creatinine testing and other tests in all individuals (or baseline + regular urinalysis in high-risk groups) No laboratory monitoring (or baseline + regular urinalysis and creatinine testing and other tests in high-risk groups) Renal toxicity, tolerability, monitoring Incidence and determinants of toxicity related to TDF and how it affects disabilityadjusted life-years (DALYs) and quality-adjusted life-years (QALYs) Adults (including pregnant or breastfeeding women), adolescents and children living with HIV Use of TDF-containing regimens Use of non-TDF-containing regimens Renal toxicity, bone toxicity, mortality related to toxicity, tolerability, morbidity related to toxicity, severity definition
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 1
WHO/HIV/2014.1
© World Health Organization 2014
2. Search strategy Embase (OvidSP): 1974-2012/wk 34 Searched 26 August 2012 1 tenofovir disoproxil/ or tenofovir disoproxil.rn. (2070) 2 tenofovir.ti,ab,ot. (3279) 3 (Apropovir or viread or atripla or tavin or tentide or Complera).af. (1006) 4 (TDF or TFV or PMPA).ti,ab,ot. (2144) 5 (gs 1278 or "gs 4331 05" or gs 433105 or gs1278 or "gs4331 05" or gs433105).ti,ab,ot. (1) 6 or/1-5 (5866) 7 human immunodeficiency virus/ or human immunodeficiency virus 1/ or human immunodeficiency virus 2/ (119389) 8 (hiv or hiv1 or hiv2).ti,ab,ot,hw. (242265) 9 (humanimmunodeficiency virus or human immunedeficiency virus or human immun$ deficiency virus).ti,ab,ot,hw. (506) 10 (human immun$ adj2 deficiency virus).ti,ab,ot,hw. (482) 11 or/7-10 (265330) 12 6 and 11 (3310) 13 animal/ or animal experiment/ (3415620) 14 (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep or ovine or monkey or monkeys).mp. (5520490) 15 or/13-14 (5520490) 16 exp human/ or human experiment/ (13832063) 17 15 not (15 and 16) (4439203) 18 12 not 17 (3197) 19 limit 18 to embase (2928) 20 remove duplicates from 19 (2927) Medline (OvidSP): 1946-2012/08/wk 3 Searched 26.8.12 1 (tenofovir or 147127-20-6).af. (2354) 2 (Apropovir or viread or atripla or tavin or tentide or Complera).af. (83) 3 (TDF or TFV or PMPA).ti,ab,ot. (1341) 4 (gs 1278 or "gs 4331 05" or gs 433105 or gs1278 or "gs4331 05" or gs433105).ti,ab,ot. (1) 5 or/1-4 (3168) 6 exp HIV/ or exp HIV Infections/ (240297) 7 (hiv or hiv1 or hiv2).ti,ab,ot,hw. (235344) 8 (humanimmunodeficiency virus or human immunedeficiency virus or human immun$ deficiency virus).ti,ab,ot,hw. (389) 9 (human immun$ adj2 deficiency virus).ti,ab,ot,hw. (386) 10 or/6-9 (275804) 11 5 and 10 (2007) 12 animals/ not (animals/ and humans/) (3678890) This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 2
WHO/HIV/2014.1
© World Health Organization 2014
13 11 not 12 (1924) 14 remove duplicates from 13 (1837) Medline In-Process Citations (OvidSP): up to 2012/08/24 Medline Daily Update (OvidSP): up to 2012/08/24 Searched 26.8.12 1 (tenofovir or 147127-20-6).af. (194) 2 (Apropovir or viread or atripla or tavin or tentide or Complera).af. (5) 3 (TDF or TFV or PMPA).ti,ab,ot. (104) 4 (gs 1278 or "gs 4331 05" or gs 433105 or gs1278 or "gs4331 05" or gs433105).ti,ab,ot. (0) 5 or/1-4 (240) 6 exp HIV/ or exp HIV Infections/ (189) 7 (hiv or hiv1 or hiv2).ti,ab,ot,hw. (8218) 8 (humanimmunodeficiency virus or human immunedeficiency virus or human immun$ deficiency virus).ti,ab,ot,hw. (19) 9 (human immun$ adj2 deficiency virus).ti,ab,ot,hw. (19) 10 or/6-9 (8230) 11 5 and 10 (153) 12 animals/ not (animals/ and humans/) (2070) 13 11 not 12 (153) 14 remove duplicates from 13 (150) CENTRAL (Cochrane Central Register of Controlled Trials): Issue 8: 2012 http://www.thecochranelibrary.com Searched 26.8.12 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14 tenofovir or 147127-20-6 345 Apropovir or viread or atripla or tavin or tentide or Complera 11 (TDF or TFV or PMPA):ti,ab 171 (gs-1278 or gs-4331-05 or gs-433105 or gs1278 or gs4331-05 or gs433105):ti,ab 0 (#1 OR #2 OR #3 OR #4) 399 MeSH descriptor HIV explode all trees 2247 MeSH descriptor HIV Infections explode all trees 6722 (hiv or hiv1 or hiv2):ti,ab,kw 8833 (human immun* deficiency virus):ti,ab 95 (humanimmunodeficiency virus):ti,ab,kw 0 (human immunedeficiency virus):ti,ab,kw 0 (#6 OR #7 OR #8 OR #9 OR #10 OR #11) 9374 (#5 AND #12) 291 (#13) 251 [limited to CENTRAL]
LILACS (Latin American and Caribbean Health Sciences): up to 2012/08/23 http://lilacs.bvsalud.org/en/ Searched 26.8.12 This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 3
WHO/HIV/2014.1
© World Health Organization 2014
Terms (date limits applied in Endnote) ((tenofovir or 147127-20-6 or Apropovir or viread or atripla or tavin or tentide or Complera or TDF or TFV or PMPA or gs-1278 or gs-4331-05 or gs-433105 or gs1278 or gs4331-05 or gs433105) AND (MH:C02.782.815.616.400 or MH:C02.800.801.400 or MH:C20.673.480 or "Infecciones por VIH" or "Infecções por HIV" or HIV or MH:B04.820.650.589.650.350 or MH:B04.909.777.731.589.650.350 or hiv or hiv1 or hiv2 or "humanimmunodeficiency virus" or "human immunedeficiency virus" or "human immun$ deficiency virus")) (tenofovir or 147127-20-6 or Apropovir or viread or atripla or tavin or tentide or Complera or TDF or TFV or PMPA or gs-1278 or gs-4331-05 or gs-433105 or gs1278 or gs4331-05 or gs433105) Total
Records 0
38
38
Spanish and Portuguese translations of MeSH terms identified using the DECS (Health Sciences Descriptors) thesaurus: http://decs.bvs.br/I/homepagei.htm Science Citation Index (SCI) (Web of Knowledge): 1970-2010/08/24 Searched 26 August 2012 Advanced search (Lemmatization off) # 12 1,775 #10 not #11 # 11 2,432,712 TS=(cat or cats or dog or dogs or animal or animals or rat or rats or hamster or hamster or feline or ovine or canine or bovine or sheep) # 10 1,872 #4 and #9 # 9 203,798 #5 or #6 or #7 or #8 # 8 480 TS=(human NEAR/2 immun* NEAR/2 deficiency NEAR/2 virus) # 7 10 TS=(human NEAR/2 immunedeficiency NEAR/2 virus) # 6 4 TS=(humanimmunodeficiency NEAR/2 virus) # 5 203,693 TS=(hiv or hiv1 or hiv2) # 4 2,951 #1 OR #2 OR #3 # 3 2 TS=(gs-1278 or gs-4331-05 or gs-433105 or gs1278 or gs4331-05 or gs433105) # 2 303 TI=(TDF or TFV or PMPA) # 1 2,800 TS=(tenofovir or 147127-20-6 OR Apropovir or viread or atripla or tavin or tentide or Complera) WHO Global Health Library (Internet): 1970-2010/08/24 http://www.globalhealthlibrary.net/php/index.php Searched 26 August 2012
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 4
WHO/HIV/2014.1
© World Health Organization 2014
Terms (tenofovir or 147127-20-6 or Apropovir or viread or atripla or tavin or tentide or Complera or TDF or TFV or PMPA or gs-1278 or gs-4331-05 or gs433105 or gs1278 or gs4331-05 or gs433105)
Records 3454 (3382 Medline) (33 LILACS)
Total (excluding Medline & LILACS records)
39
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 5
WHO/HIV/2014.1
© World Health Organization 2014
3. Flow diagram of screening process
Electronic literature search in: • • • • • • • • MEDLINE (via OvidSP) MEDLINE In-Process Citations (via OvidSP) MEDLINE Daily Update (via OvidSP) EMBASE (via Ovid SP) CENTRAL (Cochrane Central Register of Controlled Trials) LILACS (Latin American and Caribbean Health Sciences) Science Citation Index (SCI) (Web of Knowledge) WHO Global Health Library (Internet) Date of last search: 26 August 2012
References after duplicates removed (n=4188)
Titles and abstracts of references screened (n=4188)
References excluded (n=3635)
Full texts screened for eligibility (n=553)
Included: Topics (number of studies / number of publications) • Monitoring, RCTs (1/7) • Diagnostic tests (3/3) • Toxicity in adults, RCTs/RCT combinations (18/42) • Renal toxicity in adults, cohorts (7/10) • Bone toxicity in adults, cohorts (3/3) • Toxicity in children, cohorts (2/2) • Birth defects in pregnancy, prospective studies (6/6)* • Other toxicity in pregnancy than birth defects, prospective studies (3/3) • Mortality, RCTs (13/19) • Mortality, cohort (1/1) • Proteinuria, cohorts (2/2) • Economic studies (6/6) • High-risk cohorts (6/6) *Data from several studies have been included in a single registry (APR). Note Some studies relevant to several topics:Health the most prominent being the studies on mortality, forfor which the publications This work was are commissioned by the World Organization and carried out by Basel Institute Clinical Epidemiology & identified for the systematic review on the toxicity of tenofovir in adults were used (18 RCTs/RCT combinations, of which 13 Biostatistics, University Hospital Basel, Switzerland RCTs provided data mortality), and 1 further pertinent prospective cohort study was identified. During the review process, 6 WHO requested information on proteinuria, which was additionally considered.
WHO/HIV/2014.1
© World Health Organization 2014
4. Evidence summaries (Project 1: Renal toxicity monitoring with an ARV regimen containing TDF and project 4: incidence and determinants of toxicities related to TDF and its impact in DALYs or QALYs) A review on toxicities associated with the use of tenofovir (TDF) in adults showed that TDF is associated with a modest reduction of glomerular renal function and bone mineral density in short and medium term. Data from ten randomized control trials were pooled showing a mean difference in estimated glomerular filtration rate (7 studies at 48 weeks and 3 studies >48 weeks) of -2.31 mL/min (95%CI -3.93 to -0.70) among people using TDF compared to control. Data from 6 studies showed a mean decrease of bone mineral density in the lumbar spine of 1.34% (95%CI 1.73 to 0.95) and data from 5 studies a mean decrease of bone mineral density in hip of 1.39 (95%CI 1.77 to 1.00) among people receiving tenofovir. However, data on the risk for major clinical events (such as mortality, renal failure and, bone fractures) were limited and showed no difference between TDF and control users. An observational analysis of data from the DART trial showed that CKD (defined as GFR <60 ml/min/1.73 m2 or 25% decrease if <60 ml/ min/1.73 m2 pre-ART; confirmed >3 months) was a rare event but was more frequent among people starting antiretroviral therapy (ART) with tenofovir than with abacavir or nevirapine (5.9% versus 3.1% and 2.1 % through 4 years, respectively; global P<0.001). The review presented available but limited data on monitoring and long-term safety. A “post-hoc” subgroup analysis of one randomized trial showed no evidence that 12-weekly creatinine/eGFR monitoring of those taking TDF impacted the outcomes of development or worsening of chronic kidney disease (CKD), and with the monitoring, the incidence of severe eGFR was only modestly reduced. However, as TDF renal toxicity can result in a tubular defect, this damage may not be adequately measured by glomerular filtration rate alone as was used in this sub analysis. Evidence from two cohort studies with low risk of bias indicates a higher risk of proteinuria in TDF exposed ART recipients. Whether other tests, e.g. proteinuria measured by spot urine, are better suited to monitor TDF related renal toxicity compared to eGFR remains unclear. There is an urgent need for more research on these topics. The review found no evidence from high quality research with low risk of bias in children or adolescents to make a valid assessment of TDF related renal or bone toxicity. Finally, the review found no signal for an increase of malformation with intrauterine TDF exposure, based on data from the Antiretroviral Drug Registry. Although cohort studies do not indicate a higher risk of growth retardation from HIV-infected mothers with TDF exposure during pregnancy, firm conclusions cannot be drawn due to the limited number of infants and observation time. More research is needed on the effect on intrauterine TDF exposure and during breastfeeding on growth parameters among infants.
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 7
WHO/HIV/2014.1
© World Health Organization 2014
5. Bibliography of included studies 5.1. Systematic review on monitoring and diagnostic tests Table 1. References of relevant RCTs Study ID DART Trial DART 2009 Reference Studies meeting inclusion criteria
DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet, 2009, 375:123-131. GIBB, D. M., KIZITO, H., RUSSELL, E. C., CHIDZIVA, E., ZALWANGO, E., NALUMENYA, R., SPYER, M., TUMUKUNDE, D., NATHOO, K., MUNDERI, P., KYOMUGISHA, H., HAKIM, J., GROSSKURTH, H., GILKS, C. F., WALKER, A. S., MUSOKE, P. & TEAM, D. T. 2012. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Medicine, 9, e1001217. REID, A., STOEHR, W., WALKER, A. S., WILLIAMS, I. G., KITYO, C., HUGHES, P., KAMBUGU, A., GILKS, C. F., MUGYENYI, P., MUNDERI, P., HAKIM, J., GIBB, D. M. & Development of Antiretroviral Therapy Trial 2008. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clinical Infectious Diseases, 46, 1271-1281. STOHR, W., REID, A., WALKER, A. S., SSALI, F., MUNDERI, P., MAMBULE, I., KITYO, C., GROSSKURTH, H., GILKS, C. F., GIBB, D. M. & HAKIM, J. 2011. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antiviral Therapy, 16, 1011-1020. Additional publications on the trial taken into consideration
Gibb 2012
Reid 2008
Stöhr 2011
DART Trial DART 2010
DART-Trial Team 2010. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet, 375, 12331. DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/µl. AIDS 2008;22(2):237-47. DART Trial Team. (2008) Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 13: 6–16.
DART 2008a
DART 2008b
Table 2. Included studies for diagnostic tests of renal function Study ID Ravasi 2009 References of studies meeting the inclusion criteria RAVASI, G., LAURIOLA, M., TINELLI, C., BRANDOLINI, M., UGLIETTI, A. & MASERATI, R. 2009. Comparison of glomerular filtration rate estimates vs. 24-h creatinine clearance in HIV-positive patients. HIV Medicine, 10, 219-228. LABARGA, P., ALBALATE, M., BARREIRO, P., ALVAREZ, E., MARTIN-CARBONERO, L., PINILLA, J., VISPO, E., MEDRANO, J., SANCHEZ, C. A. & SORIANO, V. Glomerular filtration (GF) determined by creatinine clearance (CCR) in 24 hours urine and Cockcroft & Gault (cg) and
Labarga 2010
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 8
WHO/HIV/2014.1
© World Health Organization 2014
Study ID
References of studies meeting the inclusion criteria modification of diet in renal disease (MDRD) equations in a large cohort of HIV+ patients. Retrovirology. Conference: 16th International Symposium on HIV and Emerging Infectious Diseases, Marseille, France, 24–26 March 2010.
Vrouenraets 2012
VROUENRAETS, S. M. E., FUX, C. A., WIT, F., GARCIA, E. F., BRINKMAN, K., HOEK, F. J., VAN STRAALEN, J. P., FURRER, H., KREDIET, R. T., REISS, P. & Prepare Study Group 2012. A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function. Clinical Nephrology, 77, 311-320.
5.2. Systematic review on toxicity in adults Table 31. Included RCTs for assessment of toxicity of tenofovir Study ID A5202 (A5224s)Trial McComsey 2012 Reference Studies meeting inclusion criteria MCCOMSEY, G. A., KITCH, D., DAAR, E. S., TIERNEY, C., JAHED, N. C., MELBOURNE, K., HA, B., BROWN, T. T., BLOOM, A., FEDARKO, N. & SAX, P. E. 2012. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS, 26, 1371-1385. MCCOMSEY, G. A., KITCH, D., DAAR, E. S., TIERNEY, C., JAHED, N. C., TEBAS, P., MYERS, L., MELBOURNE, K., HA, B. & SAX, P. E. 2011. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. Journal of Infectious Diseases, 203, 1791-1801. MCCOMSEY, G. A., KITCH, D., SAX, P. E., TEBAS, P., TIERNEY, C., JAHED, N. C., MYERS, L., MELBOURNE, K., HA, B. & DAAR, E. S. 2011. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG study A5224s. Clinical Infectious Diseases, 53, 185196. Studies meeting inclusion criteria DAAR, E. S., TIERNEY, C., FISCHL, M. A., SAX, P. E., MOLLAN, K., BUDHATHOKI, C., GODFREY, C., JAHED, N. C., MYERS, L., KATZENSTEIN, D., FARAJALLAH, A., ROONEY, J. F., PAPPA, K. A., WOODWARD, W. C., PATTERSON, K., BOLIVAR, H., BENSON, C. A. & COLLIER, A. C. 2011. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Annals of Internal Medicine, 154, 445-456. SAX, P. E., et al. 2011. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. JOURNAL OF INFECTIOUS DISEASES, 204, 1191-201. SAX, P. E., TIERNEY, C., COLLIER, A. C., FISCHL, M. A., MOLLAN, K., PEEPLES, L., GODFREY, C., JAHED, N. C., MYERS, L., KATZENSTEIN, D., FARAJALLAH, A., ROONEY, J. F., HA, B., WOODWARD, W. C., KOLETAR, S. L., JOHNSON, V. A., GEISELER, P. J. & DAAR, E. S. 2009. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. New England Journal of Medicine, 361, 2230-2240.
McComsey 2011a
McComsey 2011b
A5202 Daar 2011
Sax 2011
Sax 2009
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 9
WHO/HIV/2014.1
© World Health Organization 2014
Study ID ASSERT Moyle 2010a
Reference Studies meeting inclusion criteria MOYLE, G. J., STELLBRINK, H. J., COMPSTON, J., ORKIN, C., ARRIBAS, J., DOMINGO, P., GRANIER, C., PEARCE, H., SEDANI, S. & WALLI, R. Comparison of bone and renal toxicities in the ASSERT study: final 96 week results from a prospective randomized safety trial. Antiviral Therapy. 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, London, United Kingdom, 4–6 April 2010. POST, F. A., MOYLE, G. J., STELLBRINK, H. J., DOMINGO, P., PODZAMCZER, D., FISHER, M., NORDEN, A. G., CAVASSINI, M., RIEGER, A., KHUONG-JOSSES, M.-A., BRANCO, T., PEARCE, H. C., GIVENS, N., VAVRO, C. & LIM, M. L. 2010. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. Journal of Acquired Immune Deficiency Syndromes, 55, 49-57. STELLBRINK, H. J., MOYLE, G., ORKIN, C., ARRIBAS, J. R., PEARCE, H. & ZUCCHI, P. Comparison of renal and bone toxicities, and CV serum risk markers, in the ASSERT study: 48-week results from a prospective randomised trial. HIV Medicine. 12th European AIDS Conference, EACS, Cologne, Germany, 11–14 November 2009. STELLBRINK, H. J., ORKIN, C., ARRIBAS, J. R., COMPSTON, J., GERSTOFT, J., VAN WIJNGAERDEN, E., LAZZARIN, A., RIZZARDINI, G., SPRENGER, H. G., LAMBERT, J., STURE, G., LEATHER, D., HUGHES, S., ZUCCHI, P. & PEARCE, H. 2010. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clinical Infectious Diseases, 51, 963-972. Studies meeting inclusion criteria
Post 2010
Stellbrink 2009a
Stellbrink 2010
BICOMBO/ STEAL (pooled analysis) Amin 2009
AMIN, J., DE LAZZARI, E., EMERY, S., HUMPHERIES, A., GATELL, J. M., MARTINEZ, E., CARR, A. & COOPER, D. A. Simplification with fixed-dose tenofoviremtricitabine or abacavir-lamivudine in adults with HIV infection: meta-analysis of two randomized, non-inferiority trials BICOMBO and STEAL. HIV Medicine. 12th European AIDS Conference, EACS, Cologne, Germany, 11–14 November 2009. Studies meeting inclusion criteria MARTINEZ, E., ARRANZ, J. A., PODZAMCZER, D., LONCA, M., SANZ, J., BARRAGAN, P., KNOBEL, H., RIBERA, E., GUTIERREZ, F., VALERO, S., CLOTET, B., DALMAU, D., SEGURA, F., ARRIBAS, J. R., BARRUFET, P., SANTOS, I., PAYERAS, A., DE LAZZARI, E., PICH, J. & GATELL, J. 2010. Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/ emtricitabine (TDF/FTC): 3-year results of the BICOMBO study. Journal of the International AIDS Society, 13, P43. MARTINEZ, E et al. 2009. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. Journal of Acquired Immune Deficiency Syndromes, 51, 290-7. Studies meeting inclusion criteria GALLANT, J. E., WINSTON, J. A., DEJESUS, E., POZNIAK, A. L., CHEN, S. S., CHENG, A. K. & ENEJOSA, J. V. 2008. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS,
Bicombo Martinez 2010
Martinez 2009
GS903/GS934 (pooled analysis) Gallant 2008
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 10
WHO/HIV/2014.1
© World Health Organization 2014
Study ID
Reference 22, 2155-2163.
GS903 Gallant 2004b
Studies meeting inclusion criteria GALLANT, J. E., STASZEWSKI, S., POZNIAK, A. L., DEJESUS, E., SULEIMAN, J. M. A. H., MILLER, M. D., COAKLEY, D. F., LU, B., TOOLE, J. J. & CHENG, A. K. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. Journal of the American Medical Association, 292, 191-201. IZZEDINE, H., HULOT, J. S., VITTECOQ, D., GALLANT, J. E., STASZEWSKI, S., LAUNAY-VACHER, V., CHENG, A. & DERAY, G. 2005. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrology Dialysis Transplantation, 20, 743-746. LAW, M., PULS, R., CHENG, A. K., COOPER, D. A. & CARR, A. 2006. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviralnaive adults. Antiviral Therapy, 11, 179-186. Studies meeting inclusion criteria ARRIBAS, J. R., POZNIAK, A. L., GALLANT, J. E., DEJESUS, E., GAZZARD, B., CAMPO, R. E., CHEN, S.-S., MCCOLL, D., HOLMES, C. B., ENEJOSA, J., TOOLE, J. J. & CHENG, A. K. 2008. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. Journal of Acquired Immune Deficiency Syndromes, 47, 74-8. DEJESUS, E., POZNIAK, A., GALLANT, J., ARRIBAS, J., BORG, P., ZHOU, T. & WARREN, D. Improvement in fasting lipids but minimal recovery of limb fat were seen 96 weeks after switching from lamivudine/zidovudine (CBV) plus efavirenz (EFV) to fixed-dose efavirenz/emtricitabine/tenofovir df (ATR) in HIV-infected patients. Canadian Journal of Infectious Diseases and Medical Microbiology. 19th Annual Canadian Conference on HIV/AIDS Research: New Challenges, New Commitments, CAHR 2010 Saskatoon, SK, Canada, 13–16 May 2010. 21 (3 SUPPL. SB) (pp 46B), 2010. GALLANT, J. E., DEJESUS, E., ARRIBAS, J. R., POZNIAK, A. L., GAZZARD, B., CAMPO, R. E., LU, B., MCCOLL, D., CHUCK, S., ENEJOSA, J., TOOLE, J. J. & CHENG, A. K. 2006. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New England Journal of Medicine, 354, 251-260. POZNIAK, A. L., et al. 2006. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients – virologic, immunologic, and morphologic changes – a 96-week analysis. Journal of Acquired Immune Deficiency Syndromes, 43, 535-540. Studies meeting inclusion criteria PINOLA, M., LAZZARIN, A., ANTINORI, A., CAROSI, G., DI PERRI, G., MORONI, M., VULLO, V., PASTORE, G., NORTON, M. & DI LUZIO PAPARATTI, U. 2010. Lopinavir/ritonavir + tenofovir dual therapy versus lopinavir/ritonavir-based triple therapy in HIV-infected antiretroviral naive subjects: the Kalead Study. Journal of Antivirals and Antiretrovirals, 2, 056-062. Studies meeting inclusion criteria SMITH, K. Y., PATEL, P., FINE, D., BELLOS, N., SLOAN, L., LACKEY, P., KUMAR, P. N., SUTHERLAND-PHILLIPS, D. H., VAVRO, C., YAU, L., WANNAMAKER, P. &
Izzedine 2005
Law 2006
GS934 Arribas 2008
DeJesus 2010
Gallant 2006
Pozniak 2006
Kalead Pinola 2010
HEAT Smith 2009
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 11
WHO/HIV/2014.1
© World Health Organization 2014
Study ID
Reference SHAEFER, M. S. 2009. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS, 23, 1547-1556.
PROGRESS Baran 2010
Studies meeting inclusion criteria BARAN, R. W., DIETZ, B., FREDRICK, L. M., TIAN, M. & PODSADECKI, T. HRQoL improves in treatment-naive HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC). Journal of the International AIDS Society. 10th International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom, 7–11 November 2010. QAQISH, R. B., TRINH, R., TIAN, M., FREDRICK, L., PODSADECKI, T., NORTON, M. & NILIUS, A. Bone mineral density (BMD) analysis in antiretroviral (ART)-naive subjects taking lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) or tenofovir/emtricitabine (TDF/ FTC) for 96 weeks in the PROGRESS Study. Antiviral Therapy. 13th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV, Rome, Italy, 14–16 July 2011. 16 (pp A8), 2011. REYNES, J., LAWAL, A., PULIDO, F., SOTO-MALAVE, R., GATHE, J., TIAN, M., FREDRICK, L. M., PODSADECKI, T. J. & NILIUS, A. M. 2011. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naive subjects: the PROGRESS study, 48-week results. HIV Clinical Trials, 12, 255-67. REYNES J, TRINH R, PULIDO F, SOTO-MALAVE R, GATHE J, QAQISH R, TIAN M, FREDRICK L, PODSADECKI T, NORTON M, NILIUS A. 2012. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses, 2013, 29, 256-65. Studies meeting inclusion criteria MOYLE, G. J., SABIN, C. A., CARTLEDGE, J., JOHNSON, M., WILKINS, E., CHURCHILL, D., HAY, P., FAKOYA, A., MURPHY, M., SCULLARD, G., LEEN, C. & REILLY, G. 2006. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS, 20, 2043-2050. Studies meeting inclusion criteria COOPER, V., HORNE, R. & EWAN, J. 2010. Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) plus EFV leads to improved perceptions of treatment: results from the ROCKET 1 study. Journal of the International AIDS Society, 13, P42. MOYLE, G., ORKIN, C., FISHER, M., ANDERSON, J., DHAR, J., WANG, M. H. & EWAN, J. 2010. Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24-week, randomized study. Journal of the International AIDS Society, 13, P80. ORKIN, C., MOYLE, G., FISHER, M., WANG, H. & EWAN, J. Switching from Kivexa [KVX] ABC/3TC + efavirenz [EFV] to Atripla [ATR] (EFV/FTC/TDF) reduces cholesterol in hypercholesterolemic subjects: preliminary results of a 24-week randomized study. HIV Medicine. 2nd Joint Conference of the British HIV Association and the British Association for Sexual Health and HIV, Manchester, United Kingdom, 20–23 April 2010. Studies meeting inclusion criteria MARTIN, A., BLOCH, M., AMIN, J., BAKER, D., COOPER, D. A., EMERY, S. & CARR, A. 2009. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavirlamivudine: a randomized, 96-week trial. Clinical Infectious Diseases, 49, 1591-601.
Qaqish 2011
Reynes 2011
Reynes 2012
RAVE Moyle 2006
ROCKET I Cooper 2010b
Moyle 2010c
Orkin 2010
STEAL MARTIN 2009
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 12
WHO/HIV/2014.1
© World Health Organization 2014
Study ID Bloch 2010
Reference BLOCH, M., MARTIN, A., AMIN, J., EMERY, S., CARR, A., BAKER, D. & COOPER, D. A. Predictors of limb fat changes in patients switched to tenofovir-emtricitabine or abacavirlamivudine. Antiviral Therapy. 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, London, United Kingdom, 4–6 November 2010. 15 (pp A7), 2010. Date of Publication: 2010. 2010. HASKELBERG, H., HOY, J., AMIN, J., EBELING, P. R., EMERY, S. & CARR, A. Lower fat mass and lower bone formation predict greater bone loss with tenofovir in HIV-infected adults. Antiviral Therapy. 13th International Workshop on Adverse Drug Reactions and Comorbidities in HIV, Rome, Italy, 14–16 July 2011. 16 (pp A6-A7), 2011. HASKELBERG, H. et al. 2012. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE, 7, e38377. MARTIN, A. et al. Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE, 6, e26885. Studies meeting inclusion criteria SCHOOLEY RT, RUANE P, MYERS RA, BEALL G, LAMPIRIS H, BERGER D, et al. Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study. AIDS, 2002;16(9):1257-63. Studies meeting inclusion criteria SQUIRES, K., et al. 2003. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Annals of Internal Medicine, 139, 313-20. Studies meeting inclusion criteria FISHER, M., et al. 2009. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndromes, 51, 562-8. MOYLE, G., et al. 2007. A randomized comparison of the safety of continued zidovudine plus lamivudine (Combivir, CBV) versus switching to tenofovir DF plus emtricitabine (Truvada, TVD) each plus efavirenz (EFV) in stable HIV-infected persons: results of a planned 24-week analysis. Antiviral Therapy, 12, L34-L34. Studies meeting inclusion criteria DEJESUS, E., CAMPO, R., BREDEEK, F., WANG, H., DAU, L. & FRALICH, T. SWIFT study: switching from lamivudine/ abacavir (3TC/ABC) to emtricitabine/tenofovir DF (FTC/TDF) improved fasting lipid parameters while maintaining virologic suppression. Antiviral Therapy. 13th International Workshop on Adverse Drug Reactions and Comorbidities in HIV, Rome, Italy, 14–16 July 2011. 16 (pp A55-A56), 2011. HENRY, K., DEJESUS, E., CAMPO, R., BREDEEK, U. F., WANG, H., DAU, L., PIONTKOWSKY, D. & BOSSE, M. 2012. SWIFT: switching from lamivudine/abacavir to emtricitabine/tenofovir improved lipids while maintaining virologic suppression in older HIV subjects. HIV Medicine, 13, 25-25.
Haskelberg 2011
Haskelberg 2012
Martin 2011 Study 902 Schooley 2002
Study 907 Squires 2003 SWEET Fisher 2009
Moyle 2007
SWIFT DeJesus 2011
Henry 2012
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 13
WHO/HIV/2014.1
© World Health Organization 2014
Table 4. Included non-randomized studies reporting on renal toxicity outcomes without high risk of bias Study ID DART Reid 2008 Reference Studies meeting inclusion criteria REID, A., et al. 2008. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clinical Infectious Diseases, 46, 1271-1281.
Stöhr 2011
STÖHR, W., REID, A., WALKER, A. S., SSALI, F., MUNDERI, P., MAMBULE, I., KITYO, C., GROSSKURTH, H., GILKS, C. F., GIBB, D. M. & HAKIM, J. 2011. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antiviral Therapy, 16, 1011-1020. Studies meeting inclusion criteria MOCROFT, A., KIRK, O., REISS, P., DE WIT, S., SEDLACEK, D., BENIOWSKI, M., GATELL, J., PHILLIPS, A. N., LEDERGERBER, B. & LUNDGREN, J. D. 2010. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS, 24, 1667-1678. RYOM, L., et al. Chronic kidney disease in patients with normal eGFR at baseline: results from EuroSIDA. Journal of the International AIDS Society. 10th International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom, 7–11 November 2010.
EuroSIDA Mocroft 2010
Ryom 2010
ICONA cohort Tordato 2011
Studies meeting inclusion criteria TORDATO, F., COZZI LEPRI, A., CICCONI, P., DE LUCA, A., ANTINORI, A., COLANGELI, V., CASTAGNA, A., NASTA, P., LADISA, N., GIACOMETTI, A., D’ARMINIO MONFORTE, A. & GORI, A. 2011. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Medicine, 12, 4-13. Studies meeting inclusion criteria
Johns Hopkins database Gallant 2009
GALLANT, J. E. & MOORE, R. D. 2009. Renal function with use of a tenofovircontaining initial antiretroviral regimen. AIDS, 23, 1971-5. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40(8):1194-8.
Gallant 2005
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 14
WHO/HIV/2014.1
© World Health Organization 2014
Study ID NADIS Flandre 2011
Reference Studies meeting inclusion criteria FLANDRE, P., PUGLIESE, P., CUZIN, L., BAGNIS, C. I., TACK, I., CABIE, A., POIZOT-MARTIN, I., KATLAMA, C., BRUNET-FRANCOIS, C., YAZDANPANAH, Y. & DELLAMONICA, P. 2011. Risk Factors of chronic kidney disease in HIV-infected patients. Clinical Journal of the American Society of Nephrology, 6, 1700-1707. Studies meeting inclusion criteria
Swiss HIV Cohort Study Fux 2007
FUX, C. A., et al. 2007. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral Therapy, 12, 11651173. Studies meeting inclusion criteria
Veterans Affairs HIV Clinical Case Registry (VACCR) Scherzer 2012
SCHERZER, R., ESTRELLA, M., LI, Y., CHOI, A. I., DEEKS, S. G., GRUNFELD, C. & SHLIPAK, M. G. 2012. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS, 26, 867-875.
Table 5. Included non-randomized studies reporting on bone toxicity outcomes without high risk of bias Study ID Veterans Affairs HIV Clinical Case Registry (VACCR) Bedimo 2012 Reference Studies meeting inclusion criteria
BEDIMO, R., MAALOUF, N. M., ZHANG, S., DRECHSLER, H. & TEBAS, P. 2012. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS, 26, 825-831. Studies meeting inclusion criteria
Veterans Aging Cohort Study Virtual Cohort (VACS-VC) Womack 2011
WOMACK J.A., et al. 2011. Veterans Aging Cohort Study Project Team. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One, 16;6(2):e17217. Studies meeting inclusion criteria
Women’s Interagency HIV Study
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 15
WHO/HIV/2014.1
© World Health Organization 2014
Study ID Yin 2010
Reference YIN M.T., SHI Q., HOOVER D.R., ANASTOS K., SHARMA A., YOUNG M., LEVINE A., COHEN M.H., SHANE E., GOLUB E.T., TIEN P.C. 2010. Fracture incidence in HIVinfected women: results from the Women’s Interagency HIV Study. AIDS, 24(17):267986.
5.3. Systematic review on toxicity in children and adolescents Table 6. Included studies for assessment of toxicity of tenofovir in children and adolescents RCTs Della Negra 2012 Studies meeting inclusion criteria DELLA NEGRA, M., DE CARVALHO, A. P., DE AQUINO, M. Z., DA SILVA, M. T. N., PINTO, J., WHITE, K., ARTERBURN, S., LIU, Y.-P., ENEJOSA, J. V., CHENG, A. K., CHUCK, S. L. & RHEE, M. S. 2012. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents. Pediatric Infectious Disease Journal, 31, 469-73. ROSSO, R., NASI, M., DI BIAGIO, A., REPETTO, E., DENTONE, C., PINTI, M., NEMES, E., FERRARESI, R., MUSSINI, C., ESPOSITO, R., VISCOLI, C. & COSSARIZZA, A. 2008. Effects of the change from stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: Studies on mitochondrial toxicity and thymic function. Pediatric Infectious Disease Journal, 27, 17-21. VIGANO, A., ALDROVANDI, G. M., GIACOMET, V., MERLO, M., MARTELLI, L., BERETTA, S., LURASCHI, P., ROMBOLA, G. & MORA, S. 2005. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antiviral Therapy, 10, 917-924. Studies meeting inclusion criteria ANDIMAN, W. A., et al. 2009. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatric Infectious Disease Journal, 28, 619-25. Camacho-Gonzalez et al. Tenofovir associated proximal renal tubular dysfunction in HIV-positive children and adolescents: 19th International AIDS Conference: Abstract no. MOPE066 3511 2952
Rosso 2008
1266
Vigano 2005
1732
Cohort studies Andiman 2009 (Pediatric AIDS Clinical Trials Group Study 219/219C) Camacho-Gonzalez 2012
Provided by WHO / Handsearch
5.4. Systematic review on toxicity during pregnancy Table 72. Included studies comparing the toxicity in pregnancy of regimens with TDF versus regimens without TDF (included congenital abnormalities) Study name ID/study Reference Included studies APR Registry APR Interim 2012 The Antiretroviral Pregnancy Registry Interim Report January 1989 through January 31 2012. Issued June 2012 http://www.apregistry.com/forms/interim_report.pdf access November XX 2012
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 16
WHO/HIV/2014.1
© World Health Organization 2014
Studies that are part of the APR registry Bussmann 2007 CDC Bussmann H, Wester CW, Wester CN, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr 2007;45(3):269-273. Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program 6-Digit code defect list. To access an electronic copy of the code list, go to http://www.cdc.gov/ncbddd/birthdefects/MACDP.html GIBB, D. M., et al. 2012. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Medicine, 9, e1001217. Joao EC, Calvet GA, Krauss MR, Hance LF, Ortiz J, Ivalo SA, Pierre R, Reyes M, Watts H, Read JS for the NISDI Perinatal Study Group. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI Perinatal Study. J Acquir Immune Defic Syndr 2010;53(2):176-185. Watts DH, Li D, Handelsman E, Tilson H, Paul M, Foca M, Vajaranant M, Diaz C, Tuomala R, Thompson B. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 2007; 44: 299-305.
DART Trial Gibb 2012 NISDI-Study Joao 2010
WITS Watts 2007
Table 8. Included studies on intrauterine exposure with regimens with TDF versus regimens without TDF (included studies on toxicity other than congenital abnormalities) Study name ID/study Reference Included studies DART Trial Gibb 2012 Siberry 2012 Ransom 2012 GIBB, D. M., et al. 2012. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Medicine, 9, e1001217. Siberry GK et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012;26(9):1151-9. Ransom C et al. Association of tenofovir disoproxil fumarate with neonatal growth. 19th International AIDS Conference: Abstract no.MOPE062.
5.5. Systematic review on how tenofovir toxicity affects disability-adjusted life-years and quality-adjusted life-years Table 9. Included economic studies Study ID Bendavid 2011 References of studies meeting inclusion criteria BENDAVID, E., GRANT, P., TALBOT, A., OWENS, D. K. & ZOLOPA, A. 2011. Cost-effectiveness of antiretroviral regimens in the World Health Organization’s treatment guidelines: a South African analysis. AIDS, 25, 211-220. Bischof M et al. Cost-effectiveness of first line co-formulated dual nucleoside antiretroviral therapies combined with efavirenz in HIV-infected adults in Switzerland. Unpublished report and Bucher HC IAS 2009 Abstract 1224. BROGAN, A. J., TALBIRD, S. E. & COHEN, C. 2011. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-nave adults with HIV infection in
Bischof 2009
Brogan 2011
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 17
WHO/HIV/2014.1
© World Health Organization 2014
the United States. Value in Health, 14, 657-664. Colombo 2011 COLOMBO, G. L., COLANGELI, V., DI BIAGIO, A., DI MATTEO, S., VISCOLI, C. & VIALE, P. 2011. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. ClinicoEconomics and Outcomes Research, 3, 197-205. JOUQUET, G., BYGRAVE, H., KRANZER, K., FORD, N., GADOT, L., LEE, J., HILDERBRAND, K., GOEMAERE, E., VLAHAKIS, N., TRIVINO, L., MAKAKOLE, L. & CLEARY, S. 2011. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resourcelimited setting in rural Lesotho. Journal of Acquired Immune Deficiency Syndromes, 58, e68-74. VON WYL, V., CAMBIANO, V., JORDAN, M. R., BERTAGNOLIO, S., MINERS, A., PILLAY, D., LUNDGREN, J. & PHILLIPS, A. N. 2012. Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. PLoS ONE, 7, e42834.
Jouquet 2011
Von Wyl 2012
5.6. Evidence from non-randomized (observational) studies with high risk of bias Table 10. Non-randomized studies reporting on tenofovir-related toxicity outcomes not deemed appropriate to supplement the results of the RCT (high risk of bias) Study ID California Collaborative Treatment Group (CCTG) Goicoechea 2008 Reference Studies meeting inclusion criteria
GOICOECHEA, M., LIU, S., BEST, B., SUN, S., JAIN, S., KEMPER, C., WITT, M., DIAMOND, C., HAUBRICH, R. & LOUIE, S. 2008. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. Journal of Infectious Diseases, 197, 102-108.
Chi 2010 Chi 2010
Studies meeting inclusion criteria CHI, B. H., MWANGO, A., GIGANTI, M., MULENGA, L. B., TAMBATAMBACHAPULA, B., REID, S. E., BOLTON-MOORE, C., CHINTU, N., MULENGA, P. L., STRINGER, E. M., SHENEBERGER, R., MWABA, P. & STRINGER, J. S. A. 2010. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. Journal of Acquired Immune Deficiency Syndromes, 54, 63-70.
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 18
WHO/HIV/2014.1
© World Health Organization 2014
Table 11. Non-randomized studies reporting limited information on tenofovir-related drug toxicity with high risk of bias Study ID Reginald 2012 Reginald 2012 Reference Studies meeting inclusion criteria REGINALD, O. O., HARUNA, M. M., SANI, G. B., ERIC, T. A., ADEBOLA, O. T., MATHEW, I., CHIGOZIE, I., BILKISU, U. & IBRAHIM, A. A. 2012. Adverse reactions associated with antiretroviral regimens in adult patients of a university teaching hospital HIV program in Zaria, Northern Nigeria: an observational cohort study. Journal of Antivirals and Antiretrovirals, 4, 006-013.
Parkes-Ratanshi 2009 Parkes-Ratanshi 2009
Studies meeting inclusion criteria PARKES-RATANSHI, R., WAKEHAM, K., LEVIN, J., KATENDE, D., NABIRYO, C., GROSSKURTH, H., LALLOO, D. & KAMALI, A. 2009. Anaemia in a rural cohort of HIV-infected Ugandans receiving either AZT- or non AZT-containing antiretroviral regimens. HIV Medicine, 10, 33.
Quiros-Roldan 2010 Quiros-Roldan 2010
Studies meeting inclusion criteria QUIROS-ROLDAN, E., et al. Evolution of estimated creatinine clearance by gender and type of HAART in previously naive patients over 96 week follow-up. Infection. Italian Conference on AIDS and Retroviruses, ICAR 2010, Brescia, Italy, 20–22 June 2010. 38 (pp 48-49), 2010.
This work was commissioned by the World Health Organization and carried out by Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Switzerland 19